function, life satisfaction and environment. 2 Conversely, weight loss has the potential to improve functioning and physical health among individuals with obesity. 3 Accordingly, HRQOL is an important secondary outcome in clinical trials of new interventions for weight loss. Whereas HRQOL may be broadly assessed using generic measures such as the SF-36 Health Survey (SF-36) 4 and the Sickness Impact Profile, 5 diseasespecific measures evaluate these impacts within the context of a specific health condition. Several obesity-specific measures of HRQOL have been developed, [6] [7] [8] [9] [10] including the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) questionnaire, 11 which is widely used in evaluations of diverse weight-loss interventions. [12] [13] [14] [15] [16] [17] While the IWQOL-Lite has demonstrated strong psychometric properties, 11, 18, 19 
| Study population
Psychometric analyses of the IWQOL-Lite-CT were conducted using data from two randomized trials. Study NCT02453711 (Study 1) was a multi-national, randomized, double-blind, placebo-controlled phase 2 trial of treatment with subcutaneous semaglutide for 52 weeks conducted among individuals with obesity (BMI ≥ 30 kg/m 2 ) and without diabetes. Psychometric analyses were conducted among the subset of US patients who completed the IWQOL-Lite-CT at baseline, using baseline through end-of-treatment data (n = 329). Study NCT02906930 (Study 2) was a multi-national, randomized, doubleblind, placebo-controlled phase 3a trial of treatment with oral semaglutide for 26 weeks in patients with type 2 diabetes mellitus treated with diet and exercise only (not a weight-loss trial). Psychometric analyses were conducted using baseline through end-oftreatment data among the subset of English-speaking US patients with BMI ≥ 27 kg/m 2 who completed the IWQOL-Lite-CT at baseline (n = 145). Both trials were conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki and were approved by the clinical study sites' institutional review board or independent ethics committee. In addition, all patients provided informed consent prior to their participation in the clinical trials.
| Measures
The psychometric evaluation utilized four PRO measures in addition to body weight and BMI. 
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• While the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) is in widespread use and has demonstrated strong psychometric properties, the content was initially based on the input of individuals undergoing intensive residential treatment for obesity and related comorbid conditions.
• The IWQOL-Lite may be missing some concepts that are relevant to clinical trial populations and may include concepts that are not relevant to these populations.
• As a result of these potential content validity limitations, the US Food and Drug Administration (FDA) has not allowed clinical trial results based on this measure to be described in product labelling.
WHAT THIS STUDY ADDS
• An alternative version of the IWQOL-Lite questionnaire optimized for use in patient populations typically targeted for weight loss clinical trials, the IWQOL-Lite Clinical Trials Version (IWQOL-Lite-CT), has been developed.
• The IWQOL-Lite-CT is a reliable, valid and responsive measure of weight-related functioning in the populations commonly targeted for clinical trials of new weight loss medications.
• The Physical Function scale may be particularly appropriate to support product labelling based on the proximal nature of changes in the underlying construct to changes in patients' weight.
2 (the 22-item version). Items were scored with 5-point graded response scales (1 = never, 2 = rarely, 3 = sometimes, 4 = usually, 5 = always; or 1 = not at all true, 2 = a little true, 3 = moderately true, 4 = mostly true, 5 = completely true), where lower item scores indicate higher levels of functioning.
The following PRO measures also were included in the analyses:
• The SF-36-a generic self-reported measure of perceived health status, with 36 items scored as eight multiple-item subscales (physical functioning, role limitations due to physical health problems, bodily pain, general mental health, role limitations due to emotional problems, social functioning, vitality and general health perceptions); both a Physical Component Summary (PCS) score and a
Mental Component Summary (MCS) score can also be computed
• Patient Global Impression of Change (PGI-C) items pertaining to physical functioning, mental health and overall quality of life, which assessed change compared with the beginning of the study using a 
| Analytic methods
Standard descriptive statistics were computed to characterize the samples. In addition, item-level response frequency distributions were examined for floor and ceiling effects for each IWQOL-Lite-CT item.
A floor or ceiling effect would require that more than 40% of the patients select the worst or best response category, respectively.
Exploratory factor analyses (EFAs) (Study 1) and confirmatory factor analyses (CFAs) (Study 2) were conducted to inform and confirm the structure of the IWQOL-Lite-CT, respectively. Factor structure was estimated with mean-and variance-adjusted weighted least squares estimation, and the results of the factor analyses were interpreted using model fit indices, including the root mean square error of approximation ).
In Study 1, "test" and "retest" data were IWQOL-Lite-CT responses obtained at week 48 and week 52, respectively-a relatively brief time interval during which little change was expected in subjects' weight. To further ensure a suitable sample for this analysis, only patients with less than 5% change in body weight from week 48 to week 52 were used in the test-retest reliability analyses. In Study 2, "test" and "retest" data were IWQOL-Lite-CT responses at week 0 and week 8, respectively.
Analyses were conducted using only the subset of patients with less than 5% change in body weight from week 0 to week 8 who rated themselves the same on the corresponding PGI-S at both time points.
Tests of validity involved evaluations of construct validity and dis- Table 1 presents the participant characteristics at baseline from Studies 1 and 2.
| Participant characteristics

| Response distributions
In Study 1, item-level frequency distributions generally supported the appropriateness of the response categories. However, at baseline, the following IWQOL-Lite-CT items exhibited ceiling effects (ie, reporting "never" or "not at all true"): "Unable to stand comfortably," "Selfconscious eating in social settings" and "Avoid social gatherings." In Study 2, 10 items displayed substantial ceiling effects (ie, reporting "never" or "not at all true"): "Self-conscious eating in social settings,"
"Feel judged by others," "Less important/worthy of respect," "Down or depressed about weight," "Avoid social gatherings," "Less productive," "Decreased self-esteem," "Self-conscious about weight"
and "Frustrated or upset about weight." Of note, the amount of time referenced in the item related to standing was increased prior to Study 2 (based on patient input) and did not demonstrate a ceiling effect in that subsequent study.
In Studies 1 and 2, standard descriptive statistics for each IWQOL-Lite-CT item were computed at baseline and at each assessment time point to characterize the extent to which patients with obesity and patients with overweight/obesity and type 2 diabetes experience weight-related functional impacts, and how these impacts change over time (see Tables S2 and S3 
| Structure and scoring
Inter-item correlations identified several redundancies. In Study 1, correlations between "Less important/worthy of respect" and "Feel judged by others" were 0.90 at week 28 and 0.93 at week 52, and "Decreased self-esteem" correlated excessively highly with "Selfconscious about weight" (0.92 at week 52), "Frustrated or upset about weight" (0.90 at week 28) and "Less confident" (0.91 at week 52). In Study 2, "Decreased self-esteem" correlated excessively highly with "Self-conscious about weight" and "Frustrated or upset about weight" at baseline, week 8 and week 26. Table S8 (Study 1) and Table S9 (Study 2) display the inter-item correlations for the IWQOL-Lite-CT.
Scoring was evaluated using EFAs and CFAs. Across the time points in Study 1, the EFA solutions with two factors best balanced model parsimony with acceptable fit indices (ie, RMSEA: 0.079-0.095; CFI and TLI > 0.95; SRMR < 0.05). Table 2 displays two-factor EFA solutions at week 28 and week 52 in Study 1. In the two-factor solutions at all time points, the first factor was dominated by the Physical Function items with the highest loadings, and the items related to discomfort and pain with just slightly smaller loadings. The item "Uncomfortable in small seats" also had minor loadings on the second factor at week 28 and week 52, and "Not physically active" loaded on both factors at all three time points, but was stronger on (Physical) factor 1. The second factor of the two-factor solutions contained the Psychosocial items, most of which had strong loadings. Only the items "Less productive," "Lack sufficient energy" and "Worried about health" had dual loadings on both factors at all time points, with stronger loadings on the second (Psychosocial) factor at week 28 and week 52. Table 3 presents three sets of CFA models for Study 2, analysed at all three time points using a two-factor (Psychosocial and Physical) and a three-factor (Psychosocial, Physical Function and Pain/Discomfort) structure. The first confirmatory factor structures with no cross-loading were used for simple raw scoring, and the other two were modified with double loadings to attain best fit. The strongest loadings were consistently shown in the proposed structure across CFAs. Thus, analyses supported the structure of the IWQOL-Lite-CT shown in Figure 1 .
| Reliability
Internal consistency reliability was satisfactory for all composite scores at each time point in both studies (alpha ≥0.77) (see Table S10 ). In Study (Table S11 ). In addition, in Study 1, item-level kappas ranged from 0.67 ("Less productive") to 0.82 ("Feel bad or upset about pictures of self"), indicating substantial test-retest agreement from week 48 to week 52 (data not shown).
| Validity
Cross-sectional correlational analyses provided support for the construct validity of the IWQOL-Lite-CT composite scores (Tables S12   and S13 * All composite scores demonstrated significant differences between these two groups of patients in the expected direction (Table S17 ).
In the Study 2 known-groups analyses, all composite scores were in the correct direction but were not significantly different for patients with ≥5% weight loss vs patients with weight gain at week 26 (Table S16) . However, all composite scores demonstrated statistically significant group differences in the expected direction among patients with BMI < 30 kg/m 2 vs patients with BMI > 42 kg/m 2 at weeks 8 and 26 (P < 0.01) (Table S17 ). Table 4 The improved vs unchanged Cohen's d statistics based on 5% change in body weight at week 52 tended to be greater in size than those based on improved vs unchanged PGI-C, although the week 28 analysis based on 5% change in body weight was uninformative due to the small sample size (n < 5). A parallel responsiveness analysis based on 10% change in body weight was similarly uninformative because sample sizes were less than 5 (data not shown). The IWQOL-Lite-CT items that exhibited ceiling effects (ie, "Unable to stand comfortably," "Selfconscious eating in social settings," "Avoid social gatherings," "Less important/worthy of respect," "Less interested in sexual activity" and "Less productive") had somewhat smaller responsiveness statistics, as expected (data not shown). Moreover, the items "Self-conscious eating in social settings" and "Less important/worthy of respect" had smaller responsiveness statistics than expected.
| Responsiveness
In Study 2, IWQOL-Lite-CT composite scores at week 26 yielded effect-size estimates and SRMs that were smaller than those in Study 1, which was unsurprising given that there were only minor changes in BMI from baseline to the end of the study.
| Final IWQOL-Lite-CT measure
Three items that were essentially redundant with others were eliminated from the initial 23-item IWQOL-Lite-CT described by Kolotkin and colleagues. 20 Specifically, qualitative research conducted by Notes: PGI-C improved = 1 ("much better"), 2 ("moderately better"), or 3 ("a little better"); unchanged = 4 ("no difference"); and worsened = 5 ("a little worse"), 6 ("moderately worse"), or 7 ("much worse"). Body weight improved = 5% or more weight loss, unchanged = weight change (gain or loss) less than 5%, worsened = 5% or more gain in weight.
a Using PGI-C QoL.
b
Using PGI-C PF.
c Using PGI-C PS.
d
Using both PGI-S PF and PGI-S MH or PGI-C PF and PGI-C MH.
e Using PGI-S PF or PGI-C PF.
f Using PGI-S MH or PGI-C MH.
"Decreased self-esteem" and Study 2 analyses confirmed removal of these items. The final 20-item IWQOL-Lite-CT includes two primary domains: Physical (seven items) and Psychosocial (13 items) (Table S18 ). Based on feedback from the FDA and to facilitate labelling in the United States, a five-item subset of the Physical domain, the Physical Function composite, was also evaluated and supported.
In addition, the IWQOL-Lite-CT was evaluated with Spanish speakers in Study 2 (data not shown), and the results were generally satisfactory for the small sample.
| DISCUSSION
The IWQOL-Lite-CT was rigorously developed to assess weightrelated changes in physical and psychosocial functioning in patients with overweight and obesity and in accordance with recommendations from the FDA's PRO guidance. 21 The final While the IWQOL-Lite and the IWQOL-Lite CT are intended to capture weight-related functioning in different contexts, both versions include items pertaining to physical functioning, mobility, bodily pain, self-confidence/self-esteem, productivity and sexual life.
In addition, both measures emphasize physical functioning and selfconfidence/self-esteem: whereas the IWQOL-Lite-CT contains five items relating to physical functioning and five items relating to selfconfidence/self-esteem, the IWQOL-Lite contains 14 items and seven items, respectively, relating to these concepts.
Because the IWQOL-Lite-CT has been specifically developed for use in obesity clinical trials, it addresses concerns that are specifically relevant to participants in these trials. Further, the content of the IWQOL-Lite-CT is comprehensive, covering the full range of concerns in this population, and previous qualitative research has
shown that the items are easily understood. 20 Thus, the measure may yield results that are more informative and may be more sensi- Moreover, the measure was tested on participants in pharmaceutical clinical trials for obesity, and it is unknown whether results could be generalized to other populations or settings or would be influenced by the type of weight-loss interventions. Finally, Study 2 was conducted in patients with type 2 diabetes mellitus (not a weight-loss trial), was shorter than Study 1 (26 vs 52 weeks), and yielded modest average change in weight and, consequently, modest change in IWQOL-Lite-CT scores, even among participants receiving the active treatment, which limited the opportunities for evaluation of longitudinal psychometric properties, particularly responsiveness, in this study.
| CONCLUSIONS
The IWQOL-Lite-CT is a reliable, valid, and responsive measure of weight-related functioning in populations commonly targeted for obesity clinical trials, including those for new weight-loss medications.
The Physical Function scale may be particularly appropriate to support product labelling based on the proximal nature of changes in the underlying construct to changes in patients' weight. Qualification from the FDA is being sought for use of the IWQOL-Lite-CT in clinical trials to support product approval and labelling claims. Digital versions of the questionnaire, for both web and mobile applications, are also being developed to facilitate their use in trials and improve the accuracy and reliability of reported data. 
